Statement: the primary trial does not explicitly state the dosage of Triptorelin for either of its patient cohorts. On the other hand, the secondary trial gives details of doses used for LBH589, Capecitabine and Lapatinib.
Primary_evidence: INTERVENTION 1:    Triptorelin Plus Tamoxifen   Determination of estrogen levels in blood samples from patients being treated with triptorelin plus tamoxifen for 5 years. INTERVENTION 2:    Triptorelin Plus Exemestane   Determination of estrogen levels in blood samples from patients being treated with triptorelin plus exemestane for 5 years.
Secondary_evidence: INTERVENTION 1:    LBH589 With Capecitabine   MTD, LBH589 with Capecitabine   LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.   Capecitabine: Capecitabine will be administered orally twice daily for 14 days out of every 21 days. INTERVENTION 2:    LBH589 and Lapatinib   LBH589 and Lapatinib   LBH589: LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.   Lapatinib: Lapatinib, 1000 mg PO daily will be added to this combination.